Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2020; 8(20): 4922-4929
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4922
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4922
Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report
Ping-Yang Han, Hui-Hui Chi, Yu-Tong Su, Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Ping-Yang Han, Department of Rheumatology and Immunology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Author contributions: Han PY designed the research, collected the data, and drafted the manuscript; Chi HH collected the data and revised the manuscript; Su YT designed the research and revised the manuscript; All authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China , No. 81801600 ; and Shanghai Sailing Program , No. 18YF1414500 .
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Tong Su, MD, PhD, Doctor, Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai 200025, China. suyt2015@163.com
Received: May 18, 2020
Peer-review started: May 18, 2020
First decision: June 7, 2020
Revised: June 24, 2020
Accepted: September 5, 2020
Article in press: September 5, 2020
Published online: October 26, 2020
Processing time: 160 Days and 12.7 Hours
Peer-review started: May 18, 2020
First decision: June 7, 2020
Revised: June 24, 2020
Accepted: September 5, 2020
Article in press: September 5, 2020
Published online: October 26, 2020
Processing time: 160 Days and 12.7 Hours
Core Tip
Core Tip: We report a case of idiopathic multicentric Castleman disease (iMCD) with pulmonary parenchyma and skin involvement as the primary clinical manifestations. The patient had presented to several tertiary hospitals for more than 3 years before he was finally diagnosed. iMCD is a rare systemic lymphoproliferative disease, and delays in diagnosis are common and remain a concern. Clinicians need to improve their understanding of iMCD. Combination therapy with anti-interleukin 6 (IL-6) monoclonal antibodies and glucocorticoids is an effective frontline treatment regimen, especially for those with an elevated level of serological IL-6.